AFCM
BMRN icon

Applied Finance Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Applied Finance Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,826
Closed -$207K – 233
2025
Q3 		$207K Sell
3,826
-999
-21% -$57.1K 0.01% 275
2025
Q2 		$265K Buy
+4,825
New +$284K 0.02% 271

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Applied Finance Capital Management's BMRN Position: Q4 2025 in Review

Applied Finance Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 3,826 shares — an estimated $207K sold.

Applied Finance Capital Management first reported a position in BMRN in Q2 2025 and held it in 2 quarters. The position peaked at $265K in Q2 2025. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Applied Finance Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Applied Finance Capital Management sold 3,826 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $207K.
  • Applied Finance Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Applied Finance Capital Management's BioMarin Pharmaceuticals position peaked at $265K in Q2 2025.
  • 540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Applied Finance Capital Management's 13F filing for Q4 2025, filed 5 Feb 2026.